论文部分内容阅读
公司肿瘤制药业务在未来三年有望保持35%左右的快速增长。主导产品艾素、艾恒及04年新推出的艾力将是05年的主要增长点。总体来看,公司发展战略明晰,盈利能力突出,是一家值得长期持有的质地优良公司,给予“推荐”投资评级。
The company’s oncology pharmaceutical business is expected to maintain a rapid growth of about 35% in the next three years. Leading products Ai Su, Ai Heng and the new 2004 Ai will be the main growth point in 2005. Overall, the Company has a clear development strategy and outstanding profitability. It is a well-established company worth holding for a long time and gives “recommended” investment rating.